Nitazoxanide (NTZ) exhibits broad-spectrum activity against anaerobic bacteria and 1 parasites and the ulcer causing pathogen Helicobacter pylori. Here we show that NTZ is a 2 noncompetitive inhibitor (K i 2 -10 µM) of the pyruvate ferredoxin/flavodoxin oxidoreductases 3 (PFOR) of Trichomonas vaginalis, Entamoeba histolytica, Giardia intestinalis, Clostridium 4 difficile, Clostridium perfringens, H. pylori and Campylobacter jejuni and is weakly active 5 against pyruvate dehydrogenase (PDH) of Escherichia coli. To further mechanistic studies, the 6 PFOR operon of H. pylori was cloned, over expressed in E. coli and the multi-subunit complex 7 was purified by ion exchange chromatography. Pyruvate-dependent PFOR activity with NTZ, as 8 measured by a decrease in absorbance at 418 nm (spectral shift from 418 to 351 nm), unlike 9 reduction of viologen dyes, did not result in the accumulation of products (acetyl-CoA and CO 2 ) 10 and pyruvate was not consumed in the reaction. NTZ did not displace the thiamine 11 pyrophosphate (TPP) cofactor of PFOR and the 351 nm absorbing form of NTZ was inactive. 12 Optical scans and 1 H NMR analyses determined that the spectral shift (A 418 to A 351 ) of NTZ was 13 due to protonation of the anion (NTZ -) of the 2-amino group of the thiazole ring which could be 14 generated with pure compound under acidic solutions (pKa = 6.18). We propose that NTZ -15 intercepts PFOR at an early step in formation of the lactyl-TPP transition intermediate, resulting 16 in reversal of pyruvate binding prior to decarboxylation and coordinate with proton transfer to 17 NTZ (HNTZ). Thus, NTZ might be the first example of an antimicrobial that targets the 18 "activated cofactor" of an enzymatic reaction rather than its substrate or catalytic sites: a novel 19 mechanism that may escape mutation-based drug resistance.
Nitazoxanide (2-acetyloxy-N-(5-nitro-2-thiazolyl) benzamide) (NTZ) is a broad spectrum 3 drug that is efficacious in treating infections caused by amitochondriate luminal parasites and 4 helminths (8, 15, 21, 26), and shows promise as an alternative therapy for treating infections 5 caused by Clostridium difficile (20) . More generally, NTZ appears to be an effective treatment 6 for persistent diarrhea (35) and even infections caused by rotavirus (26). NTZ, shares some 7 structural similarities with thiamine pyrophosphate (TPP) (see Figure 1) , and exhibits a similar 8 spectrum of activity as metronidazole (MTZ) and nitrofuran drugs (22), but several lines of 9 evidence suggest that this drug is mechanistically different from the redox active prodrugs (8, 18, 10 28). For example, NTZ does not increase mutation frequency or produce DNA damage in H. 11 pylori (28) and there is no cross resistance with MTZ, as MTZ-resistant strains of T. vaginalis 12 and H. pylori remain susceptible to NTZ (1, 18, 28, 34). Unlike MTZ, resistance to NTZ has not 13 been observed clinically or generated by in vitro methods commonly used to isolate MTZ R 14 mutants of H. pylori (18) . Despite the ever widening spectrum of activity reported for NTZ and 15 its therapeutic potential, little is known regarding mechanism(s) of action. 16
In support of a novel mode of action, our previous studies showed NTZ to be an inhibitor 17 of pyruvate: ferredoxin oxidoreductase (PFOR) of H. pylori (28). PFOR catalyzes the oxidative 18 and unbroken cells and then supernatants were subjected to ultracentrifugation (100,000 x g for 1 1 h) to obtain a high speed supernatant that contained PFOR activity. 2 
3
Cloning, expression and partial purification of H. pylori porDCAB. The porDCAB 4 operon was cloned into pBSK and transformed into E. coli strain JVQ2 as previously described 5 (28). E. coli expressing PFOR were pelleted by centrifugation (6000 x g) for 5 min at 4 o C, 6
washed once in phosphate buffered saline (PBS), suspended in buffer A containing 50 mM Tris-7
HCl (pH 7.4), 1 mM MgCl 2 , 1 mM DTT, 10% glycerol and passaged two to three times through 8 a French Pressure cell under nitrogen gas. The crude extract was centrifuged at 10,000 x g for 30 9
min at 4 o C to remove unbroken cells and debris and then at 100,000 x g for 1 h at 4 o C to obtain a 10 high speed supernatant containing PFOR. The protein concentration was adjusted to 25 mg/ml in 11 buffer A and the extract was applied to a diethyl-aminoethly-cellulose (DE-52) column 12 equilibrated with degassed buffer A under nitrogen. PFOR protein was eluted from the column 13 with a sodium chloride gradient prepared in buffer A (0 to 1 M NaCl) that had been degassed and 14 kept under a constant stream of nitrogen. Fractions were collected in stoppered serum bottles 15 under nitrogen as monitored with a UV-monitor (Isco). Samples from each fraction were tested 16 by rapid assay for POR activity (14, 28). PFOR containing fractions were pooled and subjected 17 to ultrafiltration dialysis (Amicon P30) in buffer A, aliquoted and either used immediately or 18 stored at -80 o C in 10% glycerol. Displacement of the TPP cofactor of PFOR by NTZ was done 19 with 3 mg/ml protein dialyzed against 10 mM NTZ, 10 mM sodium pyruvate in buffer A with 20 20% DMSO. The suspension was dialyzed three times using an Amicon 10,000 molecular 21 weight cutoff spin column. A control PFOR sample was similarly treated with 20% DMSO in 22 buffer A with 10 mM sodium pyruvate. 23
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on November 3, 2017 by guest http://aac.asm.org/ Downloaded from E. coli strain CC104 harboring either pBSK or pGS950 (vector expressing the rdxA gene 1 of H. pylori) were grown in 2% glucose minimal (MinA) liquid medium containing MTZ or 2 NTZ (0, 5, 10, 15 µg/ml) as previously described (28, 29). The turbidities of the cultures 3 (triplicate) were read at 660 nm at 16 h and normalized to percent of the control (no drug). 4 5 Enzyme assays. PFOR enzyme assays were carried out at 25 o C in 1 ml volume cuvettes 6 in a modified Cary-14 Spectrophotometer equipped with an OLIS data acquisition system (On 7
Line Instrument Co., Bogart, Georgia) (12) . PFOR (EC 1.2.7.1) was assayed under anaerobic 8 conditions with 100 mM potassium phosphate (pH 7.4), 10 mM sodium pyruvate, 5 mM benzyl 9 viologen (BV, ε = 9.2 mM -1 cm -1 at 546 nm), 0.18 mM CoA, 1 mM MgCl 2 and 5 µM TPP. The 10 reaction was started by addition of enzyme and the reduction of redox-active BV dye was 11 followed at 546 nm. PFOR was also assayed under anaerobic conditions with NTZ (28) by 12 following the decreased absorbance at 418 nm (ε = 18.64 mM -1 cm -1 ). NTZ was prepared as a 20 13 mg/ml stock solution in DMSO (65 mM). Pyruvate dehydrogenase (PDH) was assayed in 14 extracts from E. coli JVQ2 by following the reduction of NAD at 340 nm. The 1 ml reaction 15 mixture contained: 150 mM potassium phosphate buffer (pH 8.0), 3 mM sodium pyruvate, 3 mM 16
Kinetic and inhibitor analyses. The initial velocities for PFOR (H. pylori) were 1 measured at each concentration of pyruvate (0, 0.05, 0.1, 0.2, 0.4, 1, 5, 10, 20 mM) in the 2 standard assay with either BV or NTZ as electron acceptors. NTZ was then varied over a range 3 of concentrations with other components in excess to obtain kinetic constants. Concentration 4 dependent inhibition of PFOR activity by NTZ was performed with excess BV (5 mM) and 5 initial velocities were determined at each concentration of NTZ (0 -264 µM) and the decrease in 6 the initial velocity of BV reduction at each concentration of NTZ was measured 7 spectrophotometrically at 546 nm and plotted as 1/V verses I (µM NTZ) for selected organisms 8 or partly purified PFOR. 9
Determination of acetyl-CoA production. Accumulation of acetyl-CoA in the PFOR 11 reaction was determined at various times by removing aliquots of the standard PFOR reaction 12 and following treatment with perchloric acid, centrifugation and neutralization, was added to an 13 enzyme coupled reaction (19). Briefly, at each time point, 200 µl of neutralized sample was 14 assayed for acetyl-CoA in a total volume of 1.0 ml that contained 200 mM Tris-HCl pH 8.0, 5 15 mM malate, 1.5 mM NAD pH 8.0, 900 mUnits of malate dehydrogenase (from pig heart) 16 (Sigma), and 75 mUnits of citrate synthase (from pig heart) (Sigma). The amount of acetyl-CoA 17 produced was proportional to the initial velocity of NADH formation measured at 340 nm (19) . 18
The concentration of acetyl-CoA was determined from a standard curve prepared by the same 19 protocol. 20
21
Capture of 14 CO 2 . The PFOR enzyme activity was standardized for a stoppered 10 ml 22 vacutainer tube under anaerobic conditions. The reaction was started by addition of 5 µCi 23 [
14 C]pyruvate (uniformly labeled). A CO 2 trap (200 µl of a 100 mM NaOH solution) contained 1 in a borosilicate glass transport vial was inserted in the vacutainer tube. The following electron 2 acceptors were used in final concentration: 5 mM BV, 0.02 mM NTZ, 0.02 mM TIZ (tizoxanide 3 is the deacylated form of NTZ), and 0.02 mM DMSO as a control. Inhibition experiments were 4 set up to determine if NTZ competed with BV and altered CO 2 evolution. An enzyme control 5 was included in which no enzyme was added. Prior to addition of radiolabel, each tube was 6 sparged with a stream of H 2 gas through the rubber stopper to remove oxygen. 50 µl of NaOH 7 trap contents was added to 5 ml scintillation fluid and counted by liquid scintillation. Blank as 8 well as enzyme control counts were subtracted from the total count and means and standard 9 deviations were determined. 10 11 Pyruvate consumption -LDH assay. To measure the remaining pyruvate in the PFOR 12 reaction, a coupled assay with LDH was employed. For these experiments, the starting 13 concentration of pyruvate was decreased to 0.5 mM with other reagents remaining the same as 14 previously indicated. Parallel reactions were set up, and harvested entirely at 0, 1, 2, 3, 4 and 8 15 min with NTZ as electron acceptor and at 0, 0.33, 0.67, 1, 2 and 4 min with BV and processed as 16 follows. To each sample, ice-cold perchloric acid was added to a final concentration of 500 mM, 17 and incubated on ice for 40 min. Samples were then centrifuged for 5 min at 2800 X g at 4°C. 18
Supernatants were neutralized by addition of one-third volume of saturated KHCO 3 solution, 19
and again centrifuged as before. Supernatants were harvested for use in the LDH assay 20 containing 1.0 unit of LDH, 0.3 mM NADH and 100 mM potassium phosphate pH 7.5, in a total 21 volume of 1 ml. Controls for NADH oxidase were run with all reaction mixtures in the absence 22 and TIZ in DMSO. Oxidized or enzymatically reduced NTZ or TIZ were prepared as a normal 5 enzyme assay reaction. Immediately after addition of NTZ or TIZ to the reaction, or following 6 enzymatic action, samples were subjected to extraction with two volumes of 80% (v/v) 7 acetonitrile in borosilicate glass tubes, followed by centrifugation for 10 min at 8000 rpm at 4°C. 8
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For chemical reduction, samples were prepared in 100 mM potassium phosphate pH 7.5, 0.18 9 mM CoA and 5 µM TPP, and then reduced with sodium dithionite prior to extraction with 10 acetonitrile. Mass spectra were collected in negative ion mode. 11
12

NMR.
1 H NMR data were collected in DMSO-d 6 and in solutions accompanied by 13 trifluoroacetic acid, potassium ter-butoxide or triethylamine. Nitazoxanide (NTZ) is a broad spectrum antiparasitic drug that also exhibits toxicity 2 against a range of anaerobic bacteria, microaerophiles and some viruses (5, 8, 20, 21, 22, 27) . To 3 test whether PFOR is a general target of NTZ, cellular extracts were prepared from each of the 4 organisms listed in Table 1 had occurred, either an oxime (NOH) or an amine (NH 2 ) would have been produced from the 2 nitro group. The mass spectra showed no ion peaks for either of these two products. 3
NTZ inhibits E. coli growth in MinA medium. In a previous study, we noted that 15 4 µg/ml of NTZ in a glucose-based MinA medium partly inhibited growth of E. coli strain CC104 5 expressing the rdxA nitroreductase of H. pylori (28). Growth inhibition had not been previously 6 noted during MIC testing in LB based medium, which showed E. coli to be resistant to NTZ 7 (MIC >32 µg/ml). To exclude the possibility that NTZ might be activated by RdxA, E. coli 8 strains pGS950 (rdxA) and a pBSK control were grown in glucose MinA medium containing 9 various concentrations of NTZ and MTZ. We had previously established that rdxA expression 10 rendered E. coli highly susceptible to killing by MTZ (9, 29). As show in Figure 3 , MTZ was 11 inhibitory to growth of E. coli pGS950 compared with a pBSK control. In contrast, both pGS950 12 and pBSK containing strains of E. coli were inhibited 35 -80% in a dose dependent manner by 13
NTZ. The addition of LB medium to the glucose minimal medium reversed the inhibitory action 14 of NTZ (data not presented). To investigate whether NTZ was inhibitory to pyruvate 15 dehydrogenase, PDH activity was assayed in extracts of JVQ2 using NAD as electron acceptor. 16
At 20 µM, PDH was inhibited ~ 22%, sufficient perhaps to account for the partial growth 17 inhibition noted under conditions where PDH assumes a greater role in central metabolism, but 18 not sufficient for therapeutic efficacy as indicated by the high MIC against E. coli. Taken 19 together, these findings essentially rule out nitroreduction as a possible mechanism of action for 20 NTZ, and confirm a novel mechanism that is common to the PFOR class, and to a lesser extent 21 to the PDH class, of oxidative decarboxylases. Table 1 . 11
These results indicate that NTZ is a noncompetitive inhibitor of PFOR and that the drug is not 12 redox active. 13 14 NTZ does not replace TPP. To determine if NTZ, a putative structural analogue of TPP, 15 displaces TPP, PFOR was dialyzed against 10 mM NTZ and 10 mM sodium pyruvate in buffer 16 PFOR. These results also established that NTZ is consumed in the PFOR reaction and that the 1 351 nm absorbing form is no longer inhibitory. 2 3 NTZ inhibits formation of acetyl-CoA. Since NTZ appeared to intercept PFOR prior to 4 reduction of BV, we next examined cofactor requirements. We first established that reduced 5
CoA was required for PFOR activity by showing a concentration dependent increase in PFOR 6 activity in the standard BV reduction assay (see Figure 5A) . However, as also seen in Figure  7 5A, reduced CoA was not required for the PFOR reaction with NTZ, suggesting that NTZ 8 intercepts the reaction before binding of reduced CoA. To verify that acetyl-CoA was not a 9 product of the reaction with NTZ, a coupled enzyme assay was used to quantify acetyl-CoA 10 accumulation at intervals during the course of the PFOR reaction. As seen in Figure 5B results for the DMSO negative control, TIZ, NTZ, and BV are depicted in Figure 6 . There was 22 no significant increase in CO 2 evolution over controls when the reaction was conducted in the 23 presence of NTZ and TIZ, whereas, with BV, significant amounts of 14 CO 2 were generated. 1
Addition of NTZ to the BV assay significantly inhibited the evolution of CO 2 , indicating that 2 NTZ inhibits decarboxylation of pyruvate and therefore must inhibit an earlier step. 3 4 Pyruvate consumption. Since PFOR activity as measured spectrophotometrically with 5 either BV or NTZ is pyruvate dependent, we examined the possibility that NTZ might interfere 6 with formation of the C2-α-lactyl-TPP reaction intermediate or perhaps chemically change 7 pyruvate to some other product. To test these possibilities, we measured the remaining 8 concentration of pyruvate (substrate) at intervals during the PFOR enzyme reaction by coupling 9 the assay to an NADH based LDH assay. As seen in PFOR causes a molecular change in the drug as indicated by the spectral shift from 418 nm to 20 351 nm (even though there is no loss of substrate or accumulation of products) and this change 21 must be relevant to mechanism since the 351 nm form is inactive. Since the parent compound is 22 yellow in color, we speculated that an electronic rearrangement of the thiazole ring might 23 account for the spectral shift (loss of color associated with spectral shift). As seen in Figure 8A 1 the optical spectrum of NTZ changes with pH. At pH 7.4 in 100 mM potassium phosphate 2 buffer, a major absorbance peak at 418 nm is observed. In the same buffer at pH 4.0, the 3 absorbance maximum shifts to 351 nm. The denitro derivative of NTZ displays an absorption 4 maximum at 282 nm that is not influenced by changes in pH (see Figure 8A) . The form of NTZ 5 produced in the PFOR reaction shows the same spectral shift from 418 nm to 351 nm in all of the 6 enzyme reactions carried out at pH 7.4 (data not presented). This shift can be reversed by adding 7 the aprotic solvent DMSO to the cuvette, suggesting that the product of the enzyme reaction and 8 the chemical form at pH 4 might be protonated. pH titration experiments indicated that at pH 9 6.18 (pKa) both the 418 and 351 nm absorbing species are equally represented (see Figure 8B ) 10 suggesting that NTZ most likely exists as an anion under physiological conditions. on PFOR for pyruvate oxidation. MIC testing also indicates that NTZ is not active against 7
anaerobic Gram positive non-spore forming rods (Lactobacillus spp. and Propionibacterium 8 spp.) (22), which lack PFOR, or against strict aerobes and facultative anaerobes which utilize 9 PDH (5). However, the action of NTZ against organisms utilizing PDH might be influenced by 10 nutrition, as growth of E. coli in a glucose minimal medium, but not in LB medium, was 11 substantially inhibited by NTZ. Since therapeutic levels of NTZ inhibited TPP-dependent PDH 12 activity by ~25%, it is likely that other TPP-dependent enzymes such as pyruvate carboxylase or 13 transketolase might also be affected, perhaps accounting for the wide therapeutic spectrum noted 14 for this drug (5, 8, 26) . 15
Since NTZ contains a 5-nitro group on the thiazole ring, nitroreduction was considered a 16 likely mechanism of action (28). Generally, nitroreduction involves a 4e -transfer to the nitro 17 group as demonstrated by the RdxA catalyzed reduction of MTZ to hydroxylamine (9,28,29). 18
Analysis of NTZ products from the PFOR reaction by mass spectrometry indicated that 19 nitroreduction had not occurred and this conclusion was further supported by the inability of 20
RdxA in E. coli to generate toxic or DNA damaging products of NTZ (29). The nitro group of 21 NTZ is important for biological activity as substitution with bromine results in loss of activity 22 against anaerobic bacteria (22) and chemically is due to loss of resonance in the thiazole ring 1 (protonated neutral form). 2 Spectral, NMR and biochemical studies suggest that NTZ inhibits PFOR activity by a 3 novel mechanism in which the anionic form of the drug interferes with the C2-α-lactyl-TPP 4 intermediate, either before or after formation, causing dissociation of the complex. In the 5 process, the anionic NTZ -is protonated, resulting in electronic rearrangement of the nitrothiazole 6 ring detected as a spectral shift from 418 to 351 nm (see Figure 8A) . The following lines of 7 experimentation support this conclusion: (i) NTZ activity against PFOR was pyruvate dependent; 8
(ii) substrate (pyruvate) was not consumed or altered chemically in the reaction; (iii) neither CO 2 9 nor acetyl-CoA were produced as products of the reaction; (iv) NTZ did not compete for 10 reducing equivalents with redox active dyes; and (v) the protonated HNTZ form exhibiting an 11 absorbance maximum at 351 nm was no longer biologically active. The HNTZ form could be 12 produced by lowering the pH of the anion in solution from 7.4 to 4.0 (pKa 6.18) and regenerated 13 in aprotic solvents. In the absence of enzyme, there was no measurable chemical reaction 14 between NTZ, TPP and pyruvate. The change in absorbance of NTZ -in the PFOR reaction was 15 saturable (K m = 45 µM and 44 µM for the H. pylori and G. intestinalis PFORs, respectively) and 16 in competition assays, NTZ -inhibited BV reduction (K i ranged from 2 to 10 µM) until NTZ -was 17 completely converted to HNTZ. The subsequent resumption in BV reduction indicated that NTZ 18 did not replace the TPP cofactor or otherwise permanently affect PFOR enzyme function. 19
All PFORs catalyze two successive half-reactions and display ping-pong kinetics in 20 converting pyruvate to CO 2 and acetyl-CoA (2,3,23,24,25). The catalytic mechanism for the 21 PFOR class of enzymes involves enzyme-bound TPP forming a planar "V" configuration in 22 which the 4' imino group of the aminopyrimidine ring is brought close to the C2 carbon of the 23 thiazolium ring, leading to formation of a carbanion following proton abstraction from C2 1 (3, 7, 19, 24, 25) . Crystallographic studies by Cavazza et al with the PFOR of D. africanus indicate 2 that pyruvate first binds the 4' amino group of the aminopyrimidine ring before activated TPP 3 binds pyruvate at the C2 carbon of the thiazole ring, which is then followed by rapid 4 decarboxylation and release of CO 2 (2, and depicted in Figure 9B ). The absence of CO 2 5 evolution from PFOR in the presence of NTZ, suggests that NTZ must intercept this transfer 6 causing displacement of pyruvate as depicted in the model in Figure 9B . Our studies cannot 7 distinguish whether NTZ inhibits formation of the C2-α-lactylthiamine-PP intermediate by 8
acquiring a proton from the 4' amino-pyruvate complex (dissociation restores the imino group) 9 or dissociates pyruvate from the lactyl-TPP complex by attacking the OH group of the lactyl. 10
Further studies with PFOR crystals would be required to determine how NTZ interacts with the 11 transition intermediate. While these studies do not rule out a specific interaction of NTZ with the 12 PFOR enzyme, it is unlikely that iron sulfur centers are involved (the nitro group of NTZ is not 13 redox active) and kinetic data (K m and K i ) support formation of an enzyme-substrate complex 14 rather than a nonspecific association with the enzyme. 15
The selective action of NTZ for PFOR enzymes, as opposed to PDH enzymes, may be a 16 function of the reversibility of the PFOR class of enzymes as well as to the tight binding of TPP. 17 In summary, we have established that NTZ is a noncompetitive inhibitor of the PFOR 1 enzymes of anaerobic parasites, anaerobic bacteria and epsilon proteobacteria. Using the PFOR 2 of H. pylori as a model system, we determined that the anionic form of NTZ intercepts pyruvate 3 oxidation prior to decarboxylation, resulting in dissociation of the TPP-pyruvate complex 4 (releasing pyruvate) and protonation of NTZ as depicted in Figure 9B . Our studies also suggest 5 that NTZ might interfere with other TPP-requiring enzyme reactions, such as PD, which might 6 account for the wide spectrum of activity against organisms that do not express PFOR. 7
Conceptually, the targeting of cofactors of enzymatic reactions might prove a novel strategy in 8 the development of new therapeutic agents such as NTZ for which resistance would be rare, or 9 possibly non existent. 
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